Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Multiple sclerosis in 2013

Novel triggers, treatment targets and brain atrophy measures

Nature Reviews Neurology volume 10, pages 72–73 (2014)Cite this article

Subjects

2013 witnessed advances in many aspects of multiple sclerosis (MS) research. Two studies highlighted a potential role for salt as an MS trigger, and one immunomodulatory drug performed well in clinical trials. Moreover, treatment effects of MS drugs were shown to correlate inversely with brain atrophy and disease progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wu, C. et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496, 513–517 (2013).

    Article  CAS  Google Scholar 

  2. Kleinewietfeld, M. et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496, 518–522 (2013).

    Article  CAS  Google Scholar 

  3. Nicoletti, A. et al. Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case control study. Mov. Disord. 25, 2387–2394 (2010).

    Article  Google Scholar 

  4. Manouchehrinia, A. et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 136, 2298–2304 (2013).

    Article  Google Scholar 

  5. Wynn, D. et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 9, 381–390 (2010).

    Article  CAS  Google Scholar 

  6. Gold, R. et al. Daclizumab high-yield process in relapsing–remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 381, 2167–2175 (2013).

    Article  CAS  Google Scholar 

  7. International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214–219 (2011).

  8. Sormani, M. P., Arnold, D. L. & De Stefano, N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann. Neurol. http://dx.doi.org/10.1002/ana.24018.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology/Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Edifici Cemcat, Passeig de la Vall d'Hebron 119-129, Barcelona, 08035, Spain

    Xavier Montalban & Mar Tintoré

Authors
  1. Xavier Montalban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mar Tintoré
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Montalban.

Ethics declarations

Competing interests

X. Montalban has received honoraria and reimbursement for travel expenses for participation in scientific meetings, and has received fees for work performed in relation to steering committees of clinical trials. These are the companies that have paid honoraria and/or fees: Biogen Idec, Merck, Novartis, Teva, Bayer, Almirall, Genzyme, Sanofi, Roche, GeNeuro. Mar Tintoré has received honoraria and reimbursement for travel expenses for participation in scientific meetings. These are the companies that have paid honoraria and/or fees: Biogen Idec, Merck, Novartis, Teva, Bayer, Genzyme.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montalban, X., Tintoré, M. Novel triggers, treatment targets and brain atrophy measures. Nat Rev Neurol 10, 72–73 (2014). https://doi.org/10.1038/nrneurol.2013.274

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.274

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing